Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Saved in:
| Title: | Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. |
|---|---|
| Authors: | Afrough A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. Aimaz.afrough@utsouthwestern.edu., Hashmi H; Medical University of South Carolina, Charleston, SC, USA., Hansen DK; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Sidana S; Stanford University School of Medicine, Stanford, CA, USA., Ahn C; Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA., Peres LC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA., Freeman CL; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Puglianini OC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Kocoglu MH; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Atrash S; Levine Cancer Institute, Charlotte, NC, USA., Voorhees PM; Levine Cancer Institute, Charlotte, NC, USA., Shune L; The University of Kansas Medical Center, Kansas City, KS, USA., McGuirk JP; The University of Kansas Medical Center, Kansas City, KS, USA., Simmons G; Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA., Sborov DW; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Davis JA; Medical University of South Carolina, Charleston, SC, USA., Kaur G; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Sannareddy A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Ferreri CJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gaballa MR; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Goldsmith S; City of Hope National Medical Center, Duarte, CA, USA., Nadeem O; Dana-Farber Cancer Institute, Boston, MA, USA., Midha S; Dana-Farber Cancer Institute, Boston, MA, USA., Wagner CB; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Locke FL; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Patel KK; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA., Anderson LD Jr; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. larry.anderson@utsouthwestern.edu., Lin Y; Mayo Clinic, Rochester, MN, USA. |
| Source: | Blood cancer journal [Blood Cancer J] 2024 Apr 12; Vol. 14 (1), pp. 63. Date of Electronic Publication: 2024 Apr 12. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-024-00993-0 |
